By Tina Reed
The primary care industry is contracting in the face of financial challenges from the COVID-19 pandemic, according to a new survey from the Larry A. Green Center and Primary Care Collaborative.
read more
By Nick Paul Taylor
Sanofi and GlaxoSmithKline have moved their adjuvanted protein-based COVID-19 vaccine into the clinic, setting them on a path they expect to lead to a filing for approval in the first half of next year.
read more
By Angus Liu
When researchers in the U.K. said in June that the low-cost corticosteroid dexamethasone could reduce death rates in critically ill COVID-19 patients, clinicians still had doubts about whether to change their treatment practice without full data. But a new meta-analysis examining clinical trials in different parts of the world, whose findings were simultaneously published on Wednesday in JAMA, will likely change that.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Albany Molecular will perform fill-finish work on "millions" of AstraZeneca shots. The NIH selected nine more test makers to advance through its COVID diagnostics competition. The U.S. won't join WHO's COVAX, a White House spokesperson said. California could make its own generic drugs, plus many U.S. hospitals are hesitant to treat COVID patients with plasma.
read more
By Tina Reed
The funds from Bloomberg Philanthropies will go toward "significantly reducing the debt burden" of about 800 students, many who are experiencing increased financial pressure amid COVID-19.
read more
By Conor Hale
The National Institutes of Health has picked nine additional test manufacturers to advance through its “Shark Tank”-like COVID-19 diagnostics competition—alongside $129.3 million in new funding to help scale up the production of both point-of-care screening tests and high-throughput laboratory assays.
read more
By Eric Sagonowsky
Amid doubts about the FDA’s decision-making process during the pandemic, biotech CEOs on the front lines of research are laying out their approach and asking “all parties” involved in the process to adhere to high scientific standards.
read more
By Robert King
A new analysis from MedPAC found for-profit hospital systems have done a better job of weathering the COVID-19 financial crisis than their non-profit counterparts.
read more
By Kyle Blankenship
British drugmaker AstraZeneca is on a mission to lock in as many manufacturing partners as possible to support a planned global rollout for its COVID-19 vaccine frontrunner. A New York CDMO has now jumped on board, and it will commit its Southwestern facility to help pick up the slack.
read more
